Cargando…
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427515/ https://www.ncbi.nlm.nih.gov/pubmed/37233877 http://dx.doi.org/10.1007/s12325-023-02513-1 |
| _version_ | 1785090259618365440 |
|---|---|
| author | Ornstein, Moshe C. Wood, Laura S. |
| author_facet | Ornstein, Moshe C. Wood, Laura S. |
| author_sort | Ornstein, Moshe C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10427515 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104275152023-08-17 Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor Ornstein, Moshe C. Wood, Laura S. Adv Ther Commentary Springer Healthcare 2023-05-26 2023 /pmc/articles/PMC10427515/ /pubmed/37233877 http://dx.doi.org/10.1007/s12325-023-02513-1 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Commentary Ornstein, Moshe C. Wood, Laura S. Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title | Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_full | Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_fullStr | Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_full_unstemmed | Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_short | Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_sort | podcast to discuss therapy management for patients with metastatic renal cell carcinoma receiving first-line axitinib plus an immune checkpoint inhibitor |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427515/ https://www.ncbi.nlm.nih.gov/pubmed/37233877 http://dx.doi.org/10.1007/s12325-023-02513-1 |
| work_keys_str_mv | AT ornsteinmoshec podcasttodiscusstherapymanagementforpatientswithmetastaticrenalcellcarcinomareceivingfirstlineaxitinibplusanimmunecheckpointinhibitor AT woodlauras podcasttodiscusstherapymanagementforpatientswithmetastaticrenalcellcarcinomareceivingfirstlineaxitinibplusanimmunecheckpointinhibitor |